Drug Manufacturing Quality and False Claims: When the Batch Record Contradicts the Label

Manufacturing adulterated drugs can lead to a False Claims Act case when a company knowingly causes government programs to pay for medicine that materially differs from what it represents. If you work in quality assurance, manufacturing or a laboratory, you may know the difference before anyone outside the plant does. The test result, the ingredient source or the release decision can tell a different story from the product the government paid for.

What the Government Is Paying For

A drug is sold with a particular identity, strength, dosage form and label. Its approval also reaches into the plant: the application describes its composition, manufacturing facilities, methods and controls. As the Ninth Circuit explained in its decision concerning drug manufacturing representations, major manufacturing changes require approval before the changed product is distributed.

A drug is adulterated under federal drug law when its manufacturing methods, facilities or controls fail to meet current good manufacturing practice. Those controls protect the identity, strength, quality and purity promised on the label. The problem can lie in how the drug was made, even without evidence of contamination in the finished medicine.

The review Risks of Corruption in the Healthcare and Pharmaceutical Sector and the Impact of a Pandemic, published in Proceedings, Security Challenges During COVID-19 in 2021, describes manufacturing quality as a connected set of activities: ingredient proportions, batch testing and laboratory controls. That perspective matters here because the evidence can sit in several departments. The formulation, the laboratory result and the release decision each describe a different part of the same medicine.

The payment can also take different routes. A government agency may buy the drug directly, or a health care program may reimburse a claim submitted further along the supply chain. The False Claims Act reaches a manufacturer that knowingly causes false claims as well as one that submits them itself.

What Evidence Is Needed to Prove Fraud?

The useful evidence connects the drug made, the company’s knowledge, the representation and the government payment. Batch and deviation records identify the affected production and what went wrong. Laboratory results, stability testing and release records show what the company knew when it let the medicine leave.

Stability testing follows how a drug’s quality changes with time, temperature, humidity and light. It helps establish storage conditions and expiration dates and detect impurities. The date and conditions of a test therefore belong beside its result: changing them can change what the result appears to say about the drug’s shelf life.

Supplier records and approval history show whether the ingredient came from the source represented to the Food and Drug Administration. Environmental monitoring and filter records can show a problem in the production space, while internal investigations and communications with the agency show how the company described it. We connect that manufacturing account to the affected products, sales and government claims. The cases below show why each connection matters.

Cidra’s Alleged Mix-Ups Had Two Accounts

GSK’s Cidra manufacturing case ended in a $600 million civil settlement announced in 2010. The government alleged that certain batches differed materially in strength, purity or quality from the products represented in their approval documents. Its settlement agreement described split Paxil CR tablets, Avandamet tablets with incorrect amounts of an active ingredient, some nonsterile Kytril vials and some Bactroban packages containing microorganisms.

The whistleblower’s complaint alleged a separate, revealing contradiction in how the plant described tablet mix-ups. Internal investigation reports identified different drugs or strengths mixed together at the site, while reports to the Food and Drug Administration placed the problem elsewhere:

We see a basic problem with blaming the outside world for mix-ups already recorded inside the plant. The government’s civil allegation followed the affected medicine into Medicaid claims, other federal health programs and government purchases. The Justice Department announced that the whistleblower would receive approximately $96 million from the federal share of the settlement.

Ranbaxy’s Test Dates Changed the Shelf-Life Story

Ranbaxy agreed to a $350 million civil settlement in 2013 over allegations that it caused government programs to pay for drugs with strength, purity or quality that differed from their specifications, or drugs made outside their approved formulation. The Justice Department’s announcement identified Medicare, Medicaid and other federal programs among those affected.

In its guilty plea, Ranbaxy USA admitted making false statements to the Food and Drug Administration about stability-test dates. Testing took place weeks or months after the reported dates. Tests meant to occur months apart were instead conducted on the same day or within a few days, producing unreliable shelf-life results.

In the accompanying statement of facts, Ranbaxy USA also acknowledged incomplete testing records and an inadequate stability program. It admitted continuing to distribute a Sotret batch for another 13 months after learning that the batch had failed an accelerated dissolution stability test. A failed test, and still the shipments kept going. For a laboratory insider, the comparison is concrete: the original test history, the date reported outside the company and the decision to keep distributing the batch.

KVK Tech’s Case Reached the Manufacturing Computer Controls

KVK Tech agreed to a $2 million civil False Claims Act payment in the resolution announced in March 2024. The civil allegations concerned manufacturing without required computer-system controls. The case puts the systems supporting production beside the physical production itself.

For someone responsible for manufacturing systems, the useful account is what the missing control did and which production depended on it. We work through that connection with the employee, then connect the affected drugs to the government’s payment.

Qualitest’s Formula Could Not Deliver the Labeled Strength

Vintage Pharmaceuticals, doing business as Qualitest, reached a $39 million civil settlement in 2015 over fluoride tablets containing less than half the fluoride ion represented on their labels. The government alleged that the company caused Medicaid and the Federal Employees Health Benefits Program to pay for the understrength tablets. The tablets were prescribed to children in communities without fluoridated water to prevent tooth decay.

The company’s settlement admissions reached the formulation itself. Qualitest admitted using less than half the appropriate amount of sodium fluoride needed to deliver the labeled amount of fluoride ion. It also admitted knowing that federal healthcare programs were a significant source of coverage for the tablets.

The manufacturing process was not designed to produce the strength the label represented. That makes the formulation and the amount of ingredient used central evidence: the discrepancy was built into how the tablets were made. The government alleged that public programs paid for the full-strength product while children received the understrength one.

Gilead’s Alleged Ingredient Source Was Different From Its Paperwork

Gilead Sciences faced a whistleblower case alleging that it used an unapproved Chinese source for an active ingredient in HIV drugs while representing that the ingredient came from an approved South Korean manufacturer. The former employees also alleged that the company concealed failed internal testing and substituted data from replacement batches in its submission to the Food and Drug Administration. Supplier identity, batch history and submitted results supplied the alleged contradiction.

The Ninth Circuit let the whistleblowers’ case go forward in 2017. The court treated the drug names on payment requests as representations about specific approved products. That connects the purchasing and regulatory records to the claim: where the ingredient was made, how the company described it and what the government understood it was buying.

Baxter’s Mold Warning and Continued Production

Baxter Healthcare agreed to an approximately $2.158 million civil settlement in 2017 over allegations that it submitted false claims to the Department of Veterans Affairs tied to manufacturing failures at North Cove. In the accompanying criminal information, the government charged that an employee reported mold on clean-room HEPA filters to management, but production of sterile intravenous solutions continued for months with those filters in place. The Justice Department’s announcement said subsequent testing found several mold species on the filters and no evidence of impact on the IV solutions.

Under its deferred prosecution agreement, Baxter admitted distributing adulterated products in violation of federal drug law. The employee’s civil complaint also alleged that a director discouraged him from noting the apparent mold on filter certification reports. For an insider, the maintenance finding and the record of how management handled it belong together: one describes the condition, the other the company’s response.

When Does a Manufacturing Failure Become a False Claim?

A manufacturing failure supports a False Claims Act case when the evidence connects knowing deception to government payment and shows that the deception mattered to that payment. The Gilead ruling makes the practical inquiry clear: what did the company represent about the drug, what did it conceal and how did that affect the public purchase or reimbursement?

Gilead argued that continued government payments showed the alleged violations did not matter. But the parties disputed what the government knew and when. The whistleblowers also alleged that Gilead had stopped using the supplier, so later payments concerned a changed production history. We examine those relationships with you, connecting what the Food and Drug Administration was told to when the drugs were made and paid for.

What an Insider Can Connect

Quality assurance may know why a deviation remained open while a batch shipped. Laboratory staff may know why a reported result differs from the original test history. Manufacturing, environmental and supplier teams may know which conditions or ingredients changed, while regulatory staff know what the Food and Drug Administration was told. We bring those accounts together around the product and the claims for payment.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Your knowledge of how the plant actually worked gives us a place to start assessing that case, including decisions that a sales invoice alone would never explain.

You Know Why That Batch Left the Plant

If you know that the quality records contradict the medicine your company kept selling, talk with our whistleblower experts about the batch, the warning and the release decision. We work beside you to build your strongest pharmaceutical whistleblower case and bring in pharmaceutical whistleblower lawyers who understand manufacturing evidence and government payment. Your knowledge of the plant belongs at the center of that work, and we stay with you through it.